134 related articles for article (PubMed ID: 27312107)
1. Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group.
Sung L; Aplenc R; Alonzo TA; Gerbing RB; Wang YC; Meshinchi S; Gamis AS
Int J Cancer; 2016 Nov; 139(9):1930-5. PubMed ID: 27312107
[TBL] [Abstract][Full Text] [Related]
2. Associations between neutrophil recovery time, infections and relapse in pediatric acute myeloid leukemia.
Løhmann DJA; Asdahl PH; Abrahamsson J; Ha SY; Jónsson ÓG; Kaspers GJL; Koskenvuo M; Lausen B; De Moerloose B; Palle J; Zeller B; Hasle H
Pediatr Blood Cancer; 2018 Sep; 65(9):e27231. PubMed ID: 29781563
[TBL] [Abstract][Full Text] [Related]
3. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
Gamis AS; Alonzo TA; Meshinchi S; Sung L; Gerbing RB; Raimondi SC; Hirsch BA; Kahwash SB; Heerema-McKenney A; Winter L; Glick K; Davies SM; Byron P; Smith FO; Aplenc R
J Clin Oncol; 2014 Sep; 32(27):3021-32. PubMed ID: 25092781
[TBL] [Abstract][Full Text] [Related]
4. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
5. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
6. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
7. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO;
J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836
[TBL] [Abstract][Full Text] [Related]
8. Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial.
Quarello P; Fagioli F; Basso G; Putti MC; Berger M; Luciani M; Rizzari C; Menna G; Masetti R; Locatelli F
Br J Haematol; 2015 Nov; 171(4):566-73. PubMed ID: 26223157
[TBL] [Abstract][Full Text] [Related]
9. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
[TBL] [Abstract][Full Text] [Related]
10. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group.
Horan JT; Alonzo TA; Lyman GH; Gerbing RB; Lange BJ; Ravindranath Y; Becton D; Smith FO; Woods WG;
J Clin Oncol; 2008 Dec; 26(35):5797-801. PubMed ID: 18955460
[TBL] [Abstract][Full Text] [Related]
11. Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group.
Gerbing RB; Alonzo TA; Sung L; Gamis AS; Meshinchi S; Plon SE; Bertuch AA; Gramatges MM
J Clin Oncol; 2016 Nov; 34(31):3766-3772. PubMed ID: 27354474
[TBL] [Abstract][Full Text] [Related]
12. A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia.
Getz KD; Miller TP; Seif AE; Li Y; Huang YS; Bagatell R; Fisher BT; Aplenc R
Cancer Med; 2015 Sep; 4(9):1356-64. PubMed ID: 26105201
[TBL] [Abstract][Full Text] [Related]
13. Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group.
Getz KD; Li Y; Alonzo TA; Hall M; Gerbing RB; Sung L; Huang YS; Arnold S; Seif AE; Miller TP; Bagatell R; Fisher BT; Adamson PC; Gamis A; Keren R; Aplenc R
Pediatr Blood Cancer; 2015 Oct; 62(10):1775-81. PubMed ID: 25946708
[TBL] [Abstract][Full Text] [Related]
14. Outcomes in childhood AML in the absence of transplantation in first remission--Children's Cancer Group (CCG) studies 2891 and CCG 213.
Castellino SM; Alonzo TA; Buxton A; Gold S; Lange BJ; Woods WG
Pediatr Blood Cancer; 2008 Jan; 50(1):9-16. PubMed ID: 17252564
[TBL] [Abstract][Full Text] [Related]
15. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
Hsu HC; Chiu CF; Tan TD; Chau WK; Tseng CS; Ho CH
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov; 56(5):305-11. PubMed ID: 8605644
[TBL] [Abstract][Full Text] [Related]
16. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
17. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
18. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ;
Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group.
Aplenc R; Meshinchi S; Sung L; Alonzo T; Choi J; Fisher B; Gerbing R; Hirsch B; Horton T; Kahwash S; Levine J; Loken M; Brodersen L; Pollard J; Raimondi S; Kolb EA; Gamis A
Haematologica; 2020 Jul; 105(7):1879-1886. PubMed ID: 32029509
[TBL] [Abstract][Full Text] [Related]
20. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's cancer group study CCG-2891.
Gamis AS; Howells WB; DeSwarte-Wallace J; Feusner JH; Buckley JD; Woods WG
J Clin Oncol; 2000 May; 18(9):1845-55. PubMed ID: 10784625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]